T. Rowe Price Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.63B | Sell |
|
|||||
|
2025
Q1 | $4.2B | Sell |
|
|||||
|
2024
Q4 | $3.95B | Sell |
|
|||||
|
2024
Q3 | $4.9B | Sell |
|
|||||
|
2024
Q2 | $5.06B | Buy |
|
|||||
|
2024
Q1 | $4.15B | Buy |
|
|||||
|
2023
Q4 | $3.52B | Sell |
|
|||||
|
2023
Q3 | $3.64B | Buy |
|
|||||
|
2023
Q2 | $3.78B | Sell |
|
|||||
|
2023
Q1 | $4.08B | Sell |
|
|||||
|
2022
Q4 | $4.65B | Sell |
|
|||||
|
2022
Q3 | $4.14B | Sell |
|
|||||
|
2022
Q2 | $5.68B | Sell |
|
|||||
|
2022
Q1 | $6.25B | Buy |
|
|||||
|
2021
Q4 | $5.23B | Buy |
|
|||||
|
2021
Q3 | $4.94B | Buy |
|
|||||
|
2021
Q2 | $4.07B | Buy |
|
|||||
|
2021
Q1 | $2.89B | Buy |
|
|||||
|
2020
Q4 | $930M | Buy |
|
|||||
|
2020
Q3 | $858M | Buy |
|
|||||
|
2020
Q2 | $720M | Buy |
|
|||||
|
2020
Q1 | $562M | Buy |
|
|||||
|
2019
Q4 | $600M | Sell |
|
|||||
|
2019
Q3 | $546M | Sell |
|
|||||
|
2019
Q2 | $525M | Buy |
|
|||||
|
2019
Q1 | $454M | Sell |
|
|||||
|
2018
Q4 | $522M | Buy |
|
|||||
|
2018
Q3 | $522M | Sell |
|
|||||
|
2018
Q2 | $476M | Sell |
|
|||||
|
2018
Q1 | $527M | Buy |
|
|||||
|
2017
Q4 | $507M | Buy |
|
|||||
|
2017
Q3 | $483M | Buy |
|
|||||
|
2017
Q2 | $422M | Buy |
|
|||||
|
2017
Q1 | $379M | Buy |
|
|||||
|
2016
Q4 | $287M | Buy |
|
|||||
|
2016
Q3 | $41.9M | Buy |
|
|||||
|
2014
Q2 | – | Sell |
|
|||||
|
2014
Q1 | $95.2M | Sell |
|
|||||
|
2013
Q4 | $113M | Buy |
|
|||||
|
2013
Q3 | $91M | Buy |
|
|||||
|
2013
Q2 | $75M | Buy |
|